NEW YORK, Feb. 11, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of HeartWare International, Inc. (“HeartWare”) (NASDAQ:HTWR) between June 10, 2014 and January 11, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired HeartWare securities June 10, 2014 and January 11, 2016, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/heartware.
The complaint alleges that during the Class Period, HeartWare and certain of its senior executives made false and misleading statements and omitted material information. In particular, it is alleged that after the U.S. Food and Drug Administration issued a Warning Letter identifying numerous manufacturing and other regulatory failures at the Company’s sole manufacturing facility, Defendants falsely assured investors that the Company had addressed those problems, and that these concerns therefore posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is developing.
Following a series of disclosures regarding adverse effects in certain clinical trial patients, shares of HeartWare have declined from a close of $87.73 per share on June 25, 2014, to a close of just $34.50 per share on January 22, 2016.
If you suffered a loss in HeartWare you have until March 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/heartware.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 



